Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report
lanadelumab is effective and safe in preventing hereditary angioedema attacks, as well as in reducing cardiovascular risk in an immunosuppressed patient with significant comorbidities. The successful outcomes of this case highlight the potential of lanadelumab as a promising prophylactic therapy.
Authors
- Antonio Luca Brucato (ORCID: https://orcid.org/0000-0002-7566-5600)
- Leyla La Cava
- Mattia Donadoni
- Valentina Popescu Janu
- Emanuele Bizzi (ORCID: https://orcid.org/0000-0001-8560-5866)
- Chiara Cogliati (ORCID: https://orcid.org/0000-0003-2980-6158)
- Mauro Cancian (ORCID: https://orcid.org/0000-0003-2246-9144)
- Antonio Gidaro (ORCID: https://orcid.org/0000-0002-5379-1091)
- Andrea Zanichelli (ORCID: https://orcid.org/0000-0002-7512-4644)
Institutions
- University of Padua (IT)
- University of Milan (IT)
- Luigi Sacco Hospital (IT)
- IRCCS Policlinico San Donato (IT)
- Fatebenefratelli Hospital (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3389/fimmu.2024.1472390
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.44